

Take My Breath Away: The Case of Mrs. Blue

Caleb Browning

Mercy Hospital St. Louis School of Medical Laboratory Science
Class of 2014

Mary F. Signaigo

Clinical Lab Educator, Mercy Hospital St. Louis
Update 2024



Your life is our life's work.

Take My Breath Away:
The Case of Mrs. Blue

Objectives:

- Present the signs and symptom of a hemoglobinopathy.
- Describe the use of therapeutic red cell exchange by apheresis.
- Discuss alternate therapies.
- Present 10 years of treatment and follow-up.

The Case

- Patient: Mrs. Blue
- 55-year-old Caucasian female admitted to hospital September 2011
- Admitted due to shortness of breath, tingling on toes, fingers, and lips, as well as lightheadedness and fatigue

Previous Medical History

- 1965: Rheumatic Fever
- 1985-2001:
 - Hepatitis
 - Essential Hypertension
 - Mitral Valve Prolapse
 - Hyperlipidemia
 - Hypothyroidism
 - Osteoporosis

Medical History continued

Of special note regarding patient's symptoms:

- Asthma 1993
- Pulmonary fibrosis 2008
- Sleep apnea 2009
- Patent foramen ovale 2010
- Methemoglobinemia

Worsening Symptoms

- Patient had noted shortness of breath increasing in frequency since diagnosis of pulmonary fibrosis
 - Previously only occurred during exertion but now occurring even while at rest
- Lab tests were then ordered
 - BMP, LFT, CBC, Coag, and AbGs

Lab Results of Note

- 51% oxygen saturation at time of admission
 - Up to 64% four hours later
 - Normal range is >90%
- Potassium was 3.4 (low)
- Glucose 141 (high)
- Arterial oxygen partial pressure 171 (high)

Clinical Assessment

- Chronic hypoxemic, hypercapnic respiratory failure
 - Caused by combination methemoglobinemia, desquamitive interstitial lung pneumonitis, chronic interstitial lung disease, sleep apnea, asthma, patent foramen ovale, and pulmonary hypertension
 - Despite medical therapy increased shortness of breath occurring
 - Plan: Mrs. Blue will begin to receive partial exchange transfusions

Methemoglobinemia

- Disorder in which higher amounts of methemoglobin (metHb) are found in the blood
 - Methemoglobin: form of hemoglobin where ferric iron is present instead of ferrous iron
- Those with it experience headaches, fatigue, shortness of breath, cyanosis
 - In severe cases, where metHb is more than 50% of Hgb present, dysrhythmias, seizures, coma, and even death can occur

Methemoglobin

- Methemoglobin contains a ferric form, Fe^{3+} of iron unlike hemoglobin which has ferrous iron, Fe^{2+}
- Ferric iron has a decreased affinity for binding oxygen than ferrous iron
 - Ferric iron also has a greater affinity for oxygen already bound
- Result: hemoglobin that doesn't bind well and once it does bind, doesn't want to release it

Causes of Methemoglobinemia

- Congenital: very rare and due to a deficiency of NADH methemoglobin reductase, which leads to buildup of metHb
- Acquired: due to certain antibiotics and more commonly inadvertent exposure to chemicals causing an increase in metHb by nearly a thousand-fold

Congenital Methemoglobinemia

- Autosomal recessive pattern of heredity
 - 2 carrier parents leading to affected child
- Due to mutations in the gene that codes for NADH-cytochrome b5 reductase (metHb reductase)
- There are two types of congenital methemoglobinemia

Type 1 (erythrocyte reductase deficiency)

- Most common/least harmful form of congenital methemoglobinemia
- Only the red blood cells in the body lack functioning enzyme
- Patients experience the milder symptoms of the disease, most notably cyanosis of skin
 - Asymptomatic till >25% of hemoglobin is metHb

Type 2 (generalized reductase deficiency)

- Less common but more harmful
 - Roughly 10% of all cases
- Those with type 2 lack functioning enzyme throughout entire body
- Prognosis for those with type 2 very poor
 - Most experience developmental delay, intellectual disability, seizures, and failure to thrive
 - Generally, causes death within the first few years of life

Diagnosis

- Methemoglobinemia initially suspected by presence of cyanosis while arterial pO₂ is normal in ABG testing
- Can be diagnosed in-lab by co-oximetry
- Identifying the cause involves enzyme assays for methemoglobin reductase and evaluation of the patient's family pedigree

Treatment and Management of Methemoglobinemia

- Intravenous injection of methylene blue to reduce methemoglobin back to hemoglobin
 - The treatment of choice for those suffering from methemoglobinemia
 - Has toxic potential that can cause dyspnea and chest pain
- High doses ascorbic acid can be used alongside methylene blue as treatment
 - Directly reduces methemoglobin, but much slower rate

Treatment and Management of Methemoglobinemia

- In certain patients who don't respond to methylene blue or have conditions contraindicated for use
 - i.e. those with G6PD
- As an alternative these patients can receive blood through transfusion exchange as well as hyperbaric treatment
- In general, all patients will receive supplemental oxygen

Back to Mrs. Blue

- January 2012
 - Mrs. Blue went to for surgery to have a hemodialysis catheter implanted into left internal jugular vein for access during exchange transfusions
- May 2014
 - Mrs. Blue has received red cell exchanges every 3 months
 - 5-7 units transfused each time
 - Treatment appears to be sufficient

Preparation for Exchange

- The volume of blood is determined by the apheresis nurse using a pre-hematocrit, a target ending hematocrit and fraction of cells remaining and the patient's total blood volume.
- An order is placed for a type and screen and packed red blood cells with a total volume in the comments
- The weight and hematocrit is obtained for each unit.
- The average HCT of all the units should be between 58 and 62.
- The total weight is converted to mls.
- The units are electronically crossmatched and issued.

One Decade Update



Your life is our life's work.

The Case of Mrs. Blue

- Mrs. Blue has still been receiving red cell exchanges every 3 months
 - O positive, antibody screen negative
 - Phenotype: C+c+, E+e+, K= k+, Fy(a+b+), Jk(a+b=), S+s+, M=N+ (6/2023)
 - 5-7 units exchanged each time
 - 3/2024 receiving HgbS= (due to low O2 sats) and K=
 - Methyl blue is administered with exchanges, as needed
 - Ascorbic acid has been ordered multiple times but is discontinued
 - Hgb as low as 6.9 but usually well above transfusion threshold
 - Most recent exchange 11.8 before and 13.9 after

The Case of Mrs. Blue

- Mrs. Blue has still been receiving red cell exchanges every 3 months
 - O2 saturations generally improve to >80% saturation immediately after an exchange, and downtrends to the 60s prior to her next exchange.
 - She also notes a significant worsening in her fatigue/malaise prior to her exchange which has been a cause for weight loss but improves with exchange.
- Treatment still appears to be sufficient

Thank you!

We do make a difference in our patient's lives.



Your life is our life's work.